Zynerba Pharmaceuticals Stock Net Asset
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
Zynerba Pharmaceuticals fundamentals help investors to digest information that contributes to Zynerba Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zynerba Stock. The fundamental analysis module provides a way to measure Zynerba Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zynerba Pharmaceuticals stock.
Zynerba |
Zynerba Pharmaceuticals Company Net Asset Analysis
Zynerba Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Zynerba Pharmaceuticals Net Asset | 55.52 M |
Most of Zynerba Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zynerba Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Zynerba Pharmaceuticals has a Net Asset of 55.52 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Zynerba Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zynerba Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zynerba Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zynerba Pharmaceuticals by comparing valuation metrics of similar companies.Zynerba Pharmaceuticals is currently under evaluation in net asset category among its peers.
Zynerba Fundamentals
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X | |||
| EBITDA | (34.62 M) | |||
| Net Income | (35.04 M) | |||
| Cash And Equivalents | 62.49 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 334.43 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.89 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (23.03 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (0.80) X | |||
| Target Price | 1.25 | |||
| Number Of Employees | 25 | |||
| Beta | 1.19 | |||
| Market Capitalization | 70.12 M | |||
| Total Asset | 55.52 M | |||
| Retained Earnings | (274.52 M) | |||
| Working Capital | 45.6 M | |||
| Current Asset | 43.42 M | |||
| Current Liabilities | 3.94 M | |||
| Net Asset | 55.52 M |
About Zynerba Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zynerba Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zynerba Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zynerba Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |